Exhibit 99
         IMMEDIATELY


Schering-Plough Announces Sale                     Steve Galpin, Jr.
Of Wesley-Jessen Contact Lens Business             (201) 822-7415
 
 
 
 MADISON, N.J., June 29, 1995 -- Schering-Plough Corporation
 today announced the sale of its Wesley-Jessen contact lens
 business, based in Chicago, Ill., to WJ Acquisition Corp.
 (WJAC), an affiliate of Bain Capital, Inc. of Boston, for $47.5
 million in cash.  Schering-Plough is restating prior years 
 financial results in order to report Wesley-Jessen as a
 discontinued operation.
     Robert P. Luciano, chairman and chief executive officer,
 said the company decided to sell Wesley-Jessen after concluding
 it was no longer a strategic fit and that the company would
 better utilize its resources by concentrating on its primary
 businesses, the research and marketing of prescription
 pharmaceuticals and health care products.
     "Schering-Plough's pharmaceutical operations, representing
 80 percent of total company revenues, are performing extremely
 well in nearly all major therapeutic and geographic markets," 
 said Luciano, "and will continue to drive the company's growth." 
     Recalling remarks at his presentation last week to
 analysts, Luciano said the company s solid results in the 1995
 first quarter were continuing into the second quarter, which
 will produce "stronger growth rates in sales and earnings."  
 Second quarter earnings per share from operations (including
 Wesley-Jessen) are expected to increase by about 16 percent, he
 added, while earnings per share from continuing operations
 (excluding Wesley-Jessen) are expected to increase by
 approximately 20 percent.  Luciano noted that proceeds from the
 divestiture and related current tax benefits will have a
 positive effect of $85 million on the company's 1995 cash
 position.  For the year, he said that earnings per share on
 continuing operations are expected to come in at slightly more
 than $2.75, which would be $5.50 before the 2-for-1 stock split
 distributed June 9. 
     Schering-Plough will incur a one-time, second quarter
 charge for the disposal of Wesley-Jessen of approximately $156
 million after tax.  When restated to exclude Wesley-Jessen,
 Schering-Plough s 1994 net income from continuing operations
 totaled $926 million, with earnings per share of $4.84 ($2.42
 after the 2-for-1 stock split), versus previously reported
 results of $922 million in net income and $4.82 in earnings per
 share ($2.41 post-stock split).  First quarter 1995 net income
 from continuing operations, as restated, totaled $285 million,
 with earnings per share of $1.53 (77 cents post-stock split),
 versus the previously reported net income of $279 million and
 earnings per share of $1.50 (75 cents post-split).
     Wesley-Jessen is engaged in the design, manufacture and
 sale of color, toric and clear contact lenses, manufacturing
 both conventional and disposable soft contact lenses.  Wesley-
 Jessen reported 1994 revenues of $120 million.
     Merrill Lynch & Co. assisted Schering-Plough in the
 transaction.
     Schering-Plough is a research-based company engaged in the
 discovery, development, manufacturing and marketing of
 pharmaceutical and health care products worldwide.
 
                         # # #
 
 
 
 
 
 
 
 
 
 
 29-695